Search results

JuryProf. Steve LANNERS (UNamur), ChairProf. Johan WOUTERS (UNamur), SecretaryProf. Pierre FRANCOTTE (ULiège)Dr. Marie HAUFROID (UCB)Prof. Lionel POCHET (UNamur)AbstractCurrently, Mycobacterium tuberculosis remains the second deadliest infectious agent in the world, responsible for 1.6 million deaths in 2021. The burden and cost of current treatment (6 months and 4,000 euros), coupled with the alarming emergence of antibiotic-resistant strains, underscore the absolute urgency of developing new therapeutic molecules. This study focuses on the Mycobacterium tuberculosis phosphoserine phosphatase (MtSerB2), an enzyme essential for serine biosynthesis and vital to the pathogen’s survival. Furthermore, this protein plays a key role in host invasion (through its interactions with the NF-κB factor and the cellular cytoskeleton), making MtSerB2 a prime therapeutic target for the development of new, potent anti-tuberculosis drugs.One of the innovative strategies explored in this thesis is based on destabilizing the protein’s structure (disruption of protein structure). The goal is to design a molecule capable of disrupting the enzyme’s conformation, thereby causing it to lose its catalytic activity. This new class of molecules is expected to exhibit significantly higher selectivity for MtSerB2 compared to its human homolog, human phosphoserine phosphatase (hPSP).To this end, the Mycobacterium avium phosphoserine phosphatase (MaSerB) was initially used as a model system, justified by its 83% sequence identity with MtSerB2 and its propensity to crystallize rapidly. Initially, a virtual screening of drugs already available on the market was conducted to identify potential inhibitors of MaSerB. Enzymatic assays based on malachite green detectionwere then performed to evaluate the inhibitory activity of the various candidates. The results demonstrated increased selectivity of these compounds for dimeric proteins (MtSerB2 and MaSerB) compared to the human enzyme hPSP.Notably, subsequent enzymatic assays conducted directly on MtSerB2 revealed response profiles that differed from those observed with the MaSerB model. To elucidate the molecular basis of these differences, the structure of the protein in its ligand-bound state is currently being investigated. To this end, protein-inhibitor complexes have been crystallized and will be analyzed by X-ray diffraction.

JuryProf. Carine MICHIELS (UNamur), ChairProf. Anne-Catherine HEUSKIN (UNamur), SecretaryProf. Stéphane LUCAS (UNamur)Dr. Rudi LABARBE (IBA)Prof. Joao SECO (German Cancer Research Center)Prof. Simon GALAS (University of Montpellier)AbstractRadiotherapy is one of the most widely used treatments for cancer and plays a central role in modern oncology. While technological advances have greatly improved the precision of radiation delivery, damage to healthy tissues surrounding the tumor remains a major limitation. In recent years, an innovative approach known as FLASH radiotherapy has attracted considerable attention. Unlike conventional radiotherapy, FLASH delivers the therapeutic radiation dose within a fraction of a second using ultra-high dose rates. A growing body of evidence suggests that this approach may reduce radiation-induced side effects in healthy tissues while maintaining the ability to control tumours. However, the biological mechanisms responsible for this protective effect remain poorly understood.This thesis addressed two key challenges in FLASH research. The first was the development and characterization of an experimental platform capable of generating ultra-high dose rate irradiations using the ALTAÏS accelerator at the University of Namur. This work involved designing irradiation systems, validating beam dosimetry, and establishing robust experimental protocols to ensure accurate and reproducible exposure conditions. The second objective was to introduce a new biological model for FLASH investigations: the microscopic nematode Caenorhabditis elegans (C. elegans). This organism offers several advantages, including a short life cycle, ease of handling, low cost, and the conservation of many fundamental biological processes shared with higher organisms. These characteristics make it an attractive complementary model for studying radiation responses and exploring the mechanisms underlying the FLASH effect.This thesis demonstrated the suitability of C. elegans as a model for investigating biological responses to ultra-high dose rate irradiation. Studies of developmental and neurobiological endpoints across multiple irradiation conditions highlighted its potential for mechanistic FLASH research. Together, these findings provide valuable tools to advance our understanding of the FLASH effect. More broadly, they contribute to the development of safer radiotherapy strategies aimed at reducing treatment-related toxicity and improving patient quality of life.

On January 23 and 24, 2025, UNamur experts were present at the SETT (School Education Transformation Technology) trade show for its sixth edition. A must-attend event for digital education in the Wallonia-Brussels Federation, dedicated to principals, teachers and technical-pedagogical advisors.

This is a great recognition of research at UNamur: three Marie Skłodowska-Curie Doctoral Networks (DN) projects have just been awarded, with a key contribution from researchers in Namur! The first, in chemistry, involves Professor Stéphane Vincent; the second, focused on ecosystem resilience, involves Professor Frédérik de Laender; and the third, in the field of photonics, benefits from the expertise of FNRS-qualified researcher Michaël Lobet.

When a tumour develops in an organism, it is very common for the cancer cells to leave the tumour and move to another organ where they proliferate, creating what are known as metastases. This process is an important factor in mortality, as it means that the disease worsens. Hence the interest in better understanding what happens during this phenomenon. This is what the multidisciplinary team of Carine Michiels, researcher at the NARILIS Institute of UNamur, and Davide Bonifazi, researcher at the University of Vienna, did in the framework of the PACMAN research project financed by the FNRS. The results of this study are published in the journal Neoplasia.

Created on the initiative of the Belgian Nuclear Research Center SCK CEN, this Chair is awarded every two years by the F.R.S.-FNRS and the FWO to recognize a leading researcher in the field of nuclear sciences and their applications. In 2025, the Chair will pay tribute to Carine Michiels' brilliant career and her outstanding contributions to radiobiology and cancer research. 

The F.R.S.-FNRS has just published the results of its various 2024 calls. Equipment calls, research credits and projects, FRIA doctoral grants and Mandant d'Impulsion Scientifique (MIS), there are many instruments to support fundamental research. Find out more about UNamur's results.

On 15 March 2023, Prof. Henri-François Renard and Prof. Alison Forrester introduced the new advanced bioimaging tools of the UNamur Morphology & Imaging technology platform available to a broad audience of users.

Since 1996, the European Radiation Research Society (ERRS) has awarded the Bacq and Alexander Prize each year to an outstanding European researcher in recognition of the recipient's achievements in the field of radiation research. This year, the award was presented to Professor Carine Michiels, from the University of Namur.

In the summer of 2022, we set out to discover the qualified researchers at UNamur who were awarded funding by the FNRS in 2022. Today, we meet Alison Forrester, currently a postdoctoral researcher at the Institut Curie (Paris), who will soon be joining UNamur for her new term as an FNRS qualified researcher at the NARILIS Institute. Her research focuses on studying compounds that could modify the efficiency of the protein production process and thus open up new therapeutic approaches.

Jointly founded by the University of Namur and UCLouvain, the spin-off Intercept Bio aims to take a new step forward in the prevention of viral respiratory infections. Stemming from research conducted by the teams of Professor Stéphane Vincent at the UNamur Bio-Organic Chemistry Laboratory and Professor David Alsteens at the Louvain Institute of Biomolecular Science and Technology at UCLouvain, and a researcher at the WEL Research Institute, the start-up is developing a nasal spray designed to act right at the entry point for respiratory viruses: the nasal passages.

At the University of Namur, a thesis led by Fabian Delhalle, with support from SPW Research as part of the Win4Doc program, is exploring an innovative approach to producing proteins of therapeutic interest. In collaboration with Bio-Sourcing and the Walloon Center for Agricultural Research, this project aims to better understand the mechanisms of lactation in goats in order to optimize biopharmaceutical production that is more accessible, more flexible, and more environmentally friendly.